The good news is that the Chinese synopharma vaccine is coming
China National Pharmaceutical Group (CNBG), one of the leading vaccine manufacturers in China, has applied for vaccine approval. Vaccines have previously shown high efficacy in their rivals the United States and the United Kingdom.
According to Xinhua, the country's state-run news agency, on Tuesday, China National Biotech Group, a subsidiary of Sinofarm, has applied for two corona vaccines. Two different organizations are working to prepare two vaccines under CNBG. They are examining the effectiveness and safety of the vaccine. The vaccine is being tested in 10 countries in South America and the Middle East. However, information on the safety and efficacy of Synoform vaccine has not been released yet.
A senior CNBG official, however, told Xinhua Finance on condition of anonymity that no application had been made for the vaccine to be officially released. That report is not accurate. The information obtained in the third stage test of the vaccine has not yet been reviewed. When contacted by SynoPharm, the company did not comment.
Meanwhile, the world knows the results of a vaccine from US vaccine maker Pfizer and their German partner Bioentech, and another company, Modern.
Last week, Pfizer announced the results of their vaccination, as well as applying for urgent approval of the vaccine to the U.S. Food and Drug Administration. Modern will follow them quickly. On the other hand, a vaccine made by AstraZeneca and Oxford Universities in the UK is seeking approval for emergency use.
So far Russia is the only country that has approved a vaccine for general use.
According to a report in the South China Morning Post, the National Medical Products Administration, China's drug regulator, approved two CNBG vaccines for emergency use last July. The vaccine is given to high-risk people based on preliminary test data. About one million people were vaccinated under the special program.
Preliminary test results of the vaccine showed that it can produce antibodies without side effects, which is an indicator of resistance. However, to get the tick approved, the results of the third stage test have to be submitted for review.
CNBG is one of the first to start working on vaccine preparation. They first began the third stage of testing in the world. In the third phase, they tested on 50,000 volunteers. Two weeks ago, Sinofarm reported that their third-stage test was progressing rapidly and that all information related to it had exceeded expectations.
Liu Jingjen, chairman of Sinofarm, praised the safety of the vaccine, saying there were no side effects other than the mild side effects of the vaccine. It was applied to 56,000 people before the test began abroad. None of them did. The vaccine was given to 61 CNBG workers abroad. None of them did. But out of the 16 people who were not given, 10 were infected with corona.
The Covid-19 vaccine will be manufactured in two CNBG factories this year. Liu said he would make 100 million doses of vaccine this year as well as increase production capacity. The chairman of Sinofarm said that the capacity to make 100 crore dose vaccines will be created next year.